Healthcare-associated InfectionsNCT07782372
Perceptions of Leadership in Quality Culture for Infection Prevention Among Intensive Care Nurses and Unit-Based Assessment of Antimicrobial Resistance Indicators in Intensive Care Units
An observational study of Healthcare-associated Infections and Quality Culture and Leadership in Intensive Care, run by Yeliz Sapulu Alakan.
Trial summary
This study aims to examine intensive care nurses' perceptions of leadership in quality culture for infection prevention and to investigate antimicrobial resistance indicators at the intensive care unit level. Read more about this study
- Who is it for?
- Ages Up to 125 years
- Conditions the study is for
- Healthcare-associated Infections, Quality Culture and Leadership in Intensive Care, Infection Prevention and Control
- How many people
- 127 participants
- Where
- No sites listed yet
- Study dates
- 1 Sep 2026to 30 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 125 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: The study population will consist of nurses actively working in intensive care units in participating hospitals in Bursa and Iğdır, Türkiye. Eligible participants will be nurses who have been actively working in an intensive care unit for at least 1 year and who voluntarily agree to participate in the study. Student nurses, nursing interns, nurses working temporarily or on a rotational basis in intensive care units, and nurses with less than 1 year of intensive care experience will be excluded.
Who may be able to join
- Nurses who have been actively working in an intensive care unit for at least 1 year.
- Nurses who voluntarily agree to participate in the study.
Who cannot join
- Student nurses or nursing interns.
- Nurses working temporarily or on a rotational basis in the intensive care unit.
- Nurses who have been actively working in an intensive care unit for at least 1 year.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
This study aims to examine intensive care nurses' perceptions of leadership in quality culture for infection prevention and to investigate antimicrobial resistance indicators at the intensive care unit level. Healthcare-associated infections (HAIs) remain a major global patient safety problem and are associated with prolonged hospital stays, increased healthcare costs, and higher mortality. The increasing prevalence of antimicrobial resistance (AMR) further complicates infection prevention and patient care.
Intensive care units are particularly vulnerable to healthcare-associated infections and antimicrobial resistance because of the high frequency of invasive procedures, the vulnerability of critically ill patients, and the extensive use of broad-spectrum antibiotics. Nurses play a central role in infection prevention and antimicrobial stewardship because they are continuously involved in patient care. However, previous studies have reported a gap between nurses' knowledge of infection prevention and adherence to recommended practices in clinical settings. Organizational culture and leadership may contribute to this gap.
Most previous studies have focused on healthcare professionals' self-reported perceptions of infection prevention. However, limited evidence is available regarding the relationship between nurses' perceptions of leadership and quality culture and objective antimicrobial resistance indicators at the intensive care unit level. Therefore, this study will assess nurses' perceptions using the Leadership in Quality Culture for Infection Prevention (LCQ-IP) instrument and examine their relationship with retrospective microbiological data from the participating intensive care units, including antimicrobial resistance rates and resistance profiles. The findings may provide evidence on the role of organizational leadership and quality culture in infection prevention and antimicrobial resistance management in intensive care settings.
- Conditions
- Healthcare-associated Infections, Quality Culture and Leadership in Intensive Care, Infection Prevention and Control
- Keywords
- Intensive care nurses, Infection prevention and control, Quality culture, Leadership
- Medical subject headings
- Cross Infection
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Bursa | Intensive Care Nurses and Intensive Care Units in Bursa | |
| Iğdır | Intensive Care Nurses and Intensive Care Units in Iğdır |
What is being measured
The primary outcome is the main question the study is designed to answer.
Leadership in Quality Culture for Infection Prevention (LCQ-IP) score among intensive care nurses
Leadership for a culture of quality in infection prevention will be assessed using the Turkish version of the Leading a Culture of Quality for Infection Prevention Scale. The scale consists of 16 items rated on a 5-point Likert scale. Total scores range from 16 to 80, with higher scores indicating a more positive perception of leadership for a culture of quality in infection prevention.
Measured: Baseline
Secondary outcomes (1)
Antimicrobial Susceptibility Profiles of Bacterial Isolates from Intensive Care Units
Measured: The 1-year period preceding study enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Aug 2026
- Study start1 Sep 2026 (estimated)
- Primary completion30 Nov 2026 (estimated)
- Study completion30 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthcare-associated InfectionsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 127 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Yeliz Sapulu Alakan
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Yeliz Sapulu Alakan, Uludag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07782372
- Sponsor's protocol ID
- Quality Culture (LCQ-IP)
- Status last verified
- Aug 2026
- First submitted
- 17 Aug 2026
- Last updated
- 24 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant-level data will not be shared with other researchers. The study will use data collected from intensive care nurses and retrospective, unit-level microbiological and antimicrobial resistance data. Data will not be shared because of ethical, privacy, and confidentiality considerations. Only aggregated and de-identified results will be reported.
Study at a glance
From the registry record, last updated by the sponsor on 24 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Perceptions of Leadership in Quality Culture for Infection Prevention Among Intensive Care Nurses and Unit-Based Assessment of Antimicrobial Resistance Indicators in Intensive Care Units
- ClinicalTrials.gov ID
- NCT07782372
- Acronym / sponsor ID
- Quality Culture (LCQ-IP)
- Conditions
- Healthcare-associated Infections, Quality Culture and Leadership in Intensive Care, Infection Prevention and Control
- Keywords
- Intensive care nurses, Infection prevention and control, Quality culture, Leadership
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 127 participants (estimated)
- Lead sponsor
- Yeliz Sapulu AlakanUniversity, hospital or other
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- 30 Nov 2026 (estimated)
- Study completion
- 30 Dec 2026 (estimated)
- First posted
- 24 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to examine intensive care nurses' perceptions of leadership in quality culture for infection prevention and to investigate antimicrobial resistance indicators at the intensive care unit level. Healthcare-associated infections (HAIs) remain a major global patient safety problem and are associated with prolonged hospital stays, increased healthcare costs, and higher mortality. The increasing prevalence of antimicrobial resistance (AMR) further complicates infection prevention and patient care.
Intensive care units are particularly vulnerable to healthcare-associated infections and antimicrobial resistance because of the high frequency of invasive procedures, the vulnerability of critically ill patients, and the extensive use of broad-spectrum antibiotics. Nurses play a central role in infection prevention and antimicrobial stewardship because they are continuously involved in patient care. However, previous studies have reported a gap between nurses' knowledge of infection prevention and adherence to recommended practices in clinical settings. Organizational culture and leadership may contribute to this gap.
Most previous studies have focused on healthcare professionals' self-reported perceptions of infection prevention. However, limited evidence is available regarding the relationship between nurses' perceptions of leadership and quality culture and objective antimicrobial resistance indicators at the intensive care unit level. Therefore, this study will assess nurses' perceptions using the Leadership in Quality Culture for Infection Prevention (LCQ-IP) instrument and examine their relationship with retrospective microbiological data from the participating intensive care units, including antimicrobial resistance rates and resistance profiles. The findings may provide evidence on the role of organizational leadership and quality culture in infection prevention and antimicrobial resistance management in intensive care settings.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Bursa | – | –Intensive Care Nurses and Intensive Care Units in Bursa |
| Iğdır | – | –Intensive Care Nurses and Intensive Care Units in Iğdır |
Who may qualify
- Ages
- Up to 125 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The study population will consist of nurses actively working in intensive care units in participating hospitals in Bursa and Iğdır, Türkiye. Eligible participants will be nurses who have been actively working in an intensive care unit for at least 1 year and who voluntarily agree to participate in the study. Student nurses, nursing interns, nurses working temporarily or on a rotational basis in intensive care units, and nurses with less than 1 year of intensive care experience will be excluded.
Key inclusion criteria (2 listed)
- Nurses who have been actively working in an intensive care unit for at least 1 year.
- Nurses who voluntarily agree to participate in the study.
Key exclusion criteria (3 listed)
- Student nurses or nursing interns.
- Nurses working temporarily or on a rotational basis in the intensive care unit.
- Nurses who have been actively working in an intensive care unit for at least 1 year.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Leadership in Quality Culture for Infection Prevention (LCQ-IP) score among intensive care nurses
Time frame: Baseline
Leadership for a culture of quality in infection prevention will be assessed using the Turkish version of the Leading a Culture of Quality for Infection Prevention Scale. The scale consists of 16 items rated on a 5-point Likert scale. Total scores range from 16 to 80, with higher scores indicating a more positive perception of leadership for a culture of quality in infection prevention.
1 secondary outcome
Antimicrobial Susceptibility Profiles of Bacterial Isolates from Intensive Care Units
Time frame: The 1-year period preceding study enrollment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Aug 2026.
- Individual participant dataSharing planned: No. Individual participant-level data will not be shared with other researchers. The study will use data collected from intensive care nurses and retrospective, unit-level microbiological and antimicrobial resistance data. Data will not be shared because of ethical, privacy, and confidentiality considerations. Only aggregated and de-identified results will be reported.
Related trials for Healthcare-associated Infections
Not yet recruiting
Evaluation of an AI-Assisted Tool for CLABSI Surveillance at VA Medical Centers
Central Line-Associated Bloodstream Infection (CLABSI), Bacteremia
Active, not recruitingObservational study
Initial and Subsequent Healthcare-Associated Infections in Intensive Care Patients
Cross Infection, Intensive Care Units
Enrolling by invitationObservational study
Prospective Healthcare-Associated Links in Transmission of Nontuberculous Mycobacteria
Cystic Fibrosis, Nontuberculous Mycobacterial Pulmonary Infection
Not yet recruitingObservational study
Traditional Chinese Medicine in Multidrug-Resistant Bacterial Pneumonia
Multi Drug Resistant Infections, Pneumnia
Not yet recruitingObservational study
Early Identification of Pathogens in Children With Respiratory Tract Infection by Mechanical Ventilation Using mNGS
VAP - Ventilator Associated Pneumonia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Healthcare-associated Infections and Quality Culture and Leadership in Intensive Care, run by Yeliz Sapulu Alakan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 24 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yeliz Alakan, PhD lecturer (90 505 850 0222, yelizsapulu@uludag.edu.tr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Leadership in Quality Culture for Infection Prevention (LCQ-IP) score among intensive care nurses (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Aug 2026; AzTrials last refreshed its copy on 8 Nov 2026.